|
Diabetes, Vol 48, Issue 3 469-477, Copyright © 1999 by American Diabetes Association
Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice
J Liu, LE Purdy, S Rabinovitch, AM Jevnikar and JF Elliott
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
The 65KD isoform of GAD is considered to be a major target autoantigen in
many humans with autoimmune prediabetes or diabetes. The major
histocompatibility complex class II allele DQA1*0301, DQB1*0302, which
encodes HLA-DQ8, confers susceptibility to type 1 diabetes and occurs in up
to 80% of affected individuals. To map T-cell epitopes for GAD65 restricted
to the diabetes-associated DQ8 heterodimer, we generated transgenic NOD
mice expressing HLA-DQ8 and human CD4 while having the mouse class II gene
(IA(beta)) deleted. These mice were immunized with full-length purified
recombinant GAD65, and the fine specificity of T-cell responses was mapped
by examining recall responses of bulk splenocytes to an overlapping set of
20-mer peptides encompassing the entire GAD65 protein. Four different
peptides (P121-140, P201-220, P231-250, and P471-490) gave significant
T-cell recall responses. P201-220 and P231-250 have been shown previously
to bind DQ8, whereas the other two peptides had been classified as
nonbinders. Interestingly, the peptide giving the greatest response
(P201-220) encompasses residues 206-220 of GAD65, a region that has been
shown to be a dominant T-cell epitope in wild-type IA(g7) NOD mice. Overlap
in this T-cell epitope likely reflects structural similarities between DQ8
and IA(g7). The fine specificity of antibody responses in the
GAD65-immunized mice was also examined by testing the antisera by
enzyme-linked immunosorbent assay (ELISA) against the same overlapping set
of peptides. The two dominant B-cell epitopes were P361-380 and P381-400;
P121-140 and P471-490 appeared to correspond to both B- and T-cell
epitopes. Although the NOD human CD4, DQ8, IA(null) transgenic mice
generated in these studies do not develop autoimmune diabetes either
spontaneously or after cyclophosphamide treatment, they can be used to map
DQ8-restricted T-cell epitopes for a variety of human islet autoantigens.
They can also be used to test T-cell-specific reagents, such as
fluorescently labeled DQ8 tetramers containing GAD65 peptides or other
beta-cell peptides, which we believe will be useful in analyzing human
immune responses in diabetic and prediabetic patients.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. L. Hayward, N. Bautista-Lopez, K. Suzuki, A. Atrazhev, P. Dickie, and J. F. Elliott
CD4 T Cells Play Major Effector Role and CD8 T Cells Initiating Role in Spontaneous Autoimmune Myocarditis of HLA-DQ8 Transgenic IAb Knockout Nonobese Diabetic Mice.
J. Immunol.,
June 15, 2006;
176(12):
7715 - 7725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Quinn, M. McInerney, D. Huffman, B. McInerney, S. Mayo, K. Haskins, and E. Sercarz
T cells to a dominant epitope of GAD65 express a public CDR3 motif
Int. Immunol.,
June 1, 2006;
18(6):
967 - 979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Havari, A. M. Lennon-Dumenil, L. Klein, D. Neely, J. A. Taylor, M. F. McInerney, K. W. Wucherpfennig, and M. A. Lipes
Expression of the B7.1 Costimulatory Molecule on Pancreatic {beta} Cells Abrogates the Requirement for CD4 T Cells in the Development of Type 1 Diabetes
J. Immunol.,
July 15, 2004;
173(2):
787 - 796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kelemen, P. A. Gottlieb, A. L. Putnam, H. W. Davidson, D. R. Wegmann, and J. C. Hutton
HLA-DQ8-Associated T Cell Responses to the Diabetes Autoantigen Phogrin (IA-2{beta}) in Human Prediabetes
J. Immunol.,
March 15, 2004;
172(6):
3955 - 3962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Taylor, E. Havari, M. F. McInerney, R. Bronson, K. W. Wucherpfennig, and M. A. Lipes
A Spontaneous Model for Autoimmune Myocarditis Using the Human MHC Molecule HLA-DQ8
J. Immunol.,
February 15, 2004;
172(4):
2651 - 2658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Elliott, J. Liu, Z.-N. Yuan, N. Bautista-Lopez, S. L. Wallbank, K. Suzuki, D. Rayner, P. Nation, M. A. Robertson, G. Liu, et al.
Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IA{beta} knockout NOD mice
PNAS,
November 11, 2003;
100(23):
13447 - 13452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wen, F. S. Wong, J. Tang, N.-Y. Chen, M. Altieri, C. David, R. Flavell, and R. Sherwin
In Vivo Evidence for the Contribution of Human Histocompatibility Leukocyte Antigen (HLA)-DQ Molecules to the Development of Diabetes
J. Exp. Med.,
January 3, 2000;
191(1):
97 - 104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Herman, R. M. Tisch, S. D. Patel, S. L. Parry, J. Olson, J. A. Noble, A. P. Cope, B. Cox, M. Congia, and H. O. McDevitt2
Determination of Glutamic Acid Decarboxylase 65 Peptides Presented by the Type I Diabetes-Associated HLA-DQ8 Class II Molecule Identifies an Immunogenic Peptide Motif
J. Immunol.,
December 1, 1999;
163(11):
6275 - 6282.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Diabetes Association.
|
|
| |
|